Selective neuronal nitric oxide synthase (nNOS) inhibitor compounds designed with one or more thiophene-2-carboximidamide substituents for improved bioavailability.

Non-peptide azole-substituted nitric oxide snythase inhibitor compounds compositions and related methods as can be used to enhance bioavailability and inhibit production of nitric oxide.

Nitric oxide synthase (NOS) inhibitor compounds comprising bi-terminal aromatic ring moieties and related methods of NOS inhibition.

Compounds and related methods for selective inhibition of neuronal nitric oxide synthase over inducible and endothelial isoforms such compounds as can provide reduced cationic character and enhanced bioavailability.

Compounds and related compositions and methods as can be used to inhibit neuronal nitric oxide synthase and can be employed in the treatment of various neurodegenerative diseases such compounds of a formula

Compounds and related methods for selective inhibition of neuronal nitric oxide synthase over inducible and endothelial isoforms such compounds as can provide reduced cationic character and enhanced bioavailability.

Nitric oxide synthase (NOS) inhibitor compounds comprising bi-terminal aromatic ring moieties and related methods of NOS inhibition.

The present invention provides a method for treating or preventing excessive scarring including keloid and hypertrophic scars by administering 4-hydroxy tamoxifen to a patient with excessive scarring or a wound at risk for developing excessive scarring.

Methods for melanoma treatment and prevention with selective nitric oxide synthase inhibitor compounds and related pharmaceutical compositions alone or in conjunction with one or more other melanoma therapies.